pbts Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • pbt 1  (ATCC)
    91
    ATCC pbt 1
    Pbt 1, supplied by ATCC, used in various techniques. Bioz Stars score: 91/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt 1/product/ATCC
    Average 91 stars, based on 8 article reviews
    Price from $9.99 to $1999.99
    pbt 1 - by Bioz Stars, 2020-03
    91/100 stars
      Buy from Supplier

    pbts  (Takeda)
    80
    Takeda pbts
    Pbts, supplied by Takeda, used in various techniques. Bioz Stars score: 80/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbts/product/Takeda
    Average 80 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    pbts - by Bioz Stars, 2020-03
    80/100 stars
      Buy from Supplier

    98
    Thermo Fisher pbts
    Pbts, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 63 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbts/product/Thermo Fisher
    Average 98 stars, based on 63 article reviews
    Price from $9.99 to $1999.99
    pbts - by Bioz Stars, 2020-03
    98/100 stars
      Buy from Supplier

    79
    Jackson Immuno pbts
    Pbts, supplied by Jackson Immuno, used in various techniques. Bioz Stars score: 79/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbts/product/Jackson Immuno
    Average 79 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    pbts - by Bioz Stars, 2020-03
    79/100 stars
      Buy from Supplier

    86
    Cellgro pbt buffer
    Pbt Buffer, supplied by Cellgro, used in various techniques. Bioz Stars score: 86/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt buffer/product/Cellgro
    Average 86 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    pbt buffer - by Bioz Stars, 2020-03
    86/100 stars
      Buy from Supplier

    93
    Stratagene pbt lgf2
    Assays for the interaction between HpoR and LtmA. ( A ) Bacterial two-hybrid assays (Stratagene) for the interaction between HpoR and LtmA. Left panel, plate minus streptomycin (str) and 5 mM 3-amino-1,2,4-triazole (3-AT). Right panel, plate plus str and 5 mM 3-AT. CK + , co-transformant containing <t>pBT-LGF2</t> and pTRG-Gal11 P was used as a positive control. CK − , co-transformant containing pBT and pTRG was used as a negative control. ( B ) SPR assays for the specific interaction between HpoR and LtmA. HpoR was immobilized on the CM5 chip, and different concentrations of LtmA were passed over the chip.
    Pbt Lgf2, supplied by Stratagene, used in various techniques. Bioz Stars score: 93/100, based on 56 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt lgf2/product/Stratagene
    Average 93 stars, based on 56 article reviews
    Price from $9.99 to $1999.99
    pbt lgf2 - by Bioz Stars, 2020-03
    93/100 stars
      Buy from Supplier

    89
    Cellectis pbt approaches
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt Approaches, supplied by Cellectis, used in various techniques. Bioz Stars score: 89/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt approaches/product/Cellectis
    Average 89 stars, based on 4 article reviews
    Price from $9.99 to $1999.99
    pbt approaches - by Bioz Stars, 2020-03
    89/100 stars
      Buy from Supplier

    82
    Avanti Polar phosphatidylbutanol pbt
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Phosphatidylbutanol Pbt, supplied by Avanti Polar, used in various techniques. Bioz Stars score: 82/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphatidylbutanol pbt/product/Avanti Polar
    Average 82 stars, based on 11 article reviews
    Price from $9.99 to $1999.99
    phosphatidylbutanol pbt - by Bioz Stars, 2020-03
    82/100 stars
      Buy from Supplier

    89
    Stratagene pbt vector
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt Vector, supplied by Stratagene, used in various techniques. Bioz Stars score: 89/100, based on 45 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt vector/product/Stratagene
    Average 89 stars, based on 45 article reviews
    Price from $9.99 to $1999.99
    pbt vector - by Bioz Stars, 2020-03
    89/100 stars
      Buy from Supplier

    81
    Agilent technologies pbt plasmid
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt Plasmid, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 81/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt plasmid/product/Agilent technologies
    Average 81 stars, based on 14 article reviews
    Price from $9.99 to $1999.99
    pbt plasmid - by Bioz Stars, 2020-03
    81/100 stars
      Buy from Supplier

    99
    Developmental Studies Hybridoma Bank pbt
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 99/100, based on 142 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Developmental Studies Hybridoma Bank
    Average 99 stars, based on 142 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    99/100 stars
      Buy from Supplier

    90
    Epitope Biotech pbt
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt, supplied by Epitope Biotech, used in various techniques. Bioz Stars score: 90/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Epitope Biotech
    Average 90 stars, based on 8 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    90/100 stars
      Buy from Supplier

    94
    Eppendorf AG pbt
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt, supplied by Eppendorf AG, used in various techniques. Bioz Stars score: 94/100, based on 21 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Eppendorf AG
    Average 94 stars, based on 21 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    94/100 stars
      Buy from Supplier

    90
    Fisher Scientific pbt
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Fisher Scientific
    Average 90 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    90/100 stars
      Buy from Supplier

    99
    Jackson Immuno pbt
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt, supplied by Jackson Immuno, used in various techniques. Bioz Stars score: 99/100, based on 332 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Jackson Immuno
    Average 99 stars, based on 332 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    99/100 stars
      Buy from Supplier

    99
    Millipore pbt
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt, supplied by Millipore, used in various techniques. Bioz Stars score: 99/100, based on 527 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Millipore
    Average 99 stars, based on 527 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    99/100 stars
      Buy from Supplier

    pbt  (Roche)
    99
    Roche pbt
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt, supplied by Roche, used in various techniques. Bioz Stars score: 99/100, based on 166 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Roche
    Average 99 stars, based on 166 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    99/100 stars
      Buy from Supplier

    90
    Rockland Immunochemicals pbt
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 90/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Rockland Immunochemicals
    Average 90 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    90/100 stars
      Buy from Supplier

    99
    Stratagene pbt
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt, supplied by Stratagene, used in various techniques. Bioz Stars score: 99/100, based on 61 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Stratagene
    Average 99 stars, based on 61 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    99/100 stars
      Buy from Supplier

    99
    Thermo Fisher pbt
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1143 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Thermo Fisher
    Average 99 stars, based on 1143 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    99/100 stars
      Buy from Supplier

    82
    Cell Signaling Technology Inc pbt ngs bre
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt Ngs Bre, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 82/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt ngs bre/product/Cell Signaling Technology Inc
    Average 82 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    pbt ngs bre - by Bioz Stars, 2020-03
    82/100 stars
      Buy from Supplier

    90
    BBI Solutions pbt
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt, supplied by BBI Solutions, used in various techniques. Bioz Stars score: 90/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/BBI Solutions
    Average 90 stars, based on 16 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    90/100 stars
      Buy from Supplier

    pbt  (Nacalai)
    99
    Nacalai pbt
    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic <t>iPSC</t> ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor <t>PBT</t> and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )
    Pbt, supplied by Nacalai, used in various techniques. Bioz Stars score: 99/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Nacalai
    Average 99 stars, based on 8 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    99/100 stars
      Buy from Supplier

    91
    Agilent technologies pbt
    Primary breast tumor <t>(PBT)</t> and corresponding <t>CRC</t> of case 6, representative of the TNBC subtype. A : Phase contrast image of CRC co-culture, showing the feeder cells (short arrows) and an epithelial cell colony (cobblestone cell morphology) (40x); B : Flow cytometry histogram showing CRC cells stained for PE/CD326 (EpCAM) (red peaks); unlabeled control (black peaks). Number of gated cells > 10,000; C : Ploidy analysis showing a DNA index of 3.01(G1 aneuploidy yellow peak) in relation to the diploid control (Peripheral Blood Lymphocyte (PBL)—G1 diploid red peak); E : FFPE tissue section (40x) and F : tumor area microdissected for the molecular analysis (400x); D and G : Genomic profile plots of the PBT and corresponding CRC, respectively; H . Next generation sequencing analysis of CRCs and corresponding PBTs showing the retention of specific somatic variants on the TP53 , KDR , PIK3CA , CDKN2 and JAK3 genes in the CRCs.
    Pbt, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 91/100, based on 40 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Agilent technologies
    Average 91 stars, based on 40 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    91/100 stars
      Buy from Supplier

    95
    GE Healthcare pbt
    Primary breast tumor <t>(PBT)</t> and corresponding <t>CRC</t> of case 6, representative of the TNBC subtype. A : Phase contrast image of CRC co-culture, showing the feeder cells (short arrows) and an epithelial cell colony (cobblestone cell morphology) (40x); B : Flow cytometry histogram showing CRC cells stained for PE/CD326 (EpCAM) (red peaks); unlabeled control (black peaks). Number of gated cells > 10,000; C : Ploidy analysis showing a DNA index of 3.01(G1 aneuploidy yellow peak) in relation to the diploid control (Peripheral Blood Lymphocyte (PBL)—G1 diploid red peak); E : FFPE tissue section (40x) and F : tumor area microdissected for the molecular analysis (400x); D and G : Genomic profile plots of the PBT and corresponding CRC, respectively; H . Next generation sequencing analysis of CRCs and corresponding PBTs showing the retention of specific somatic variants on the TP53 , KDR , PIK3CA , CDKN2 and JAK3 genes in the CRCs.
    Pbt, supplied by GE Healthcare, used in various techniques. Bioz Stars score: 95/100, based on 35 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/GE Healthcare
    Average 95 stars, based on 35 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    95/100 stars
      Buy from Supplier

    pbt  (Promega)
    91
    Promega pbt
    Primary breast tumor <t>(PBT)</t> and corresponding <t>CRC</t> of case 6, representative of the TNBC subtype. A : Phase contrast image of CRC co-culture, showing the feeder cells (short arrows) and an epithelial cell colony (cobblestone cell morphology) (40x); B : Flow cytometry histogram showing CRC cells stained for PE/CD326 (EpCAM) (red peaks); unlabeled control (black peaks). Number of gated cells > 10,000; C : Ploidy analysis showing a DNA index of 3.01(G1 aneuploidy yellow peak) in relation to the diploid control (Peripheral Blood Lymphocyte (PBL)—G1 diploid red peak); E : FFPE tissue section (40x) and F : tumor area microdissected for the molecular analysis (400x); D and G : Genomic profile plots of the PBT and corresponding CRC, respectively; H . Next generation sequencing analysis of CRCs and corresponding PBTs showing the retention of specific somatic variants on the TP53 , KDR , PIK3CA , CDKN2 and JAK3 genes in the CRCs.
    Pbt, supplied by Promega, used in various techniques. Bioz Stars score: 91/100, based on 42 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Promega
    Average 91 stars, based on 42 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    91/100 stars
      Buy from Supplier

    99
    The Jackson Laboratory pbt
    Primary breast tumor <t>(PBT)</t> and corresponding <t>CRC</t> of case 6, representative of the TNBC subtype. A : Phase contrast image of CRC co-culture, showing the feeder cells (short arrows) and an epithelial cell colony (cobblestone cell morphology) (40x); B : Flow cytometry histogram showing CRC cells stained for PE/CD326 (EpCAM) (red peaks); unlabeled control (black peaks). Number of gated cells > 10,000; C : Ploidy analysis showing a DNA index of 3.01(G1 aneuploidy yellow peak) in relation to the diploid control (Peripheral Blood Lymphocyte (PBL)—G1 diploid red peak); E : FFPE tissue section (40x) and F : tumor area microdissected for the molecular analysis (400x); D and G : Genomic profile plots of the PBT and corresponding CRC, respectively; H . Next generation sequencing analysis of CRCs and corresponding PBTs showing the retention of specific somatic variants on the TP53 , KDR , PIK3CA , CDKN2 and JAK3 genes in the CRCs.
    Pbt, supplied by The Jackson Laboratory, used in various techniques. Bioz Stars score: 99/100, based on 42 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/The Jackson Laboratory
    Average 99 stars, based on 42 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    99/100 stars
      Buy from Supplier

    pbt  (Valiant)
    93
    Valiant pbt
    Primary breast tumor <t>(PBT)</t> and corresponding <t>CRC</t> of case 6, representative of the TNBC subtype. A : Phase contrast image of CRC co-culture, showing the feeder cells (short arrows) and an epithelial cell colony (cobblestone cell morphology) (40x); B : Flow cytometry histogram showing CRC cells stained for PE/CD326 (EpCAM) (red peaks); unlabeled control (black peaks). Number of gated cells > 10,000; C : Ploidy analysis showing a DNA index of 3.01(G1 aneuploidy yellow peak) in relation to the diploid control (Peripheral Blood Lymphocyte (PBL)—G1 diploid red peak); E : FFPE tissue section (40x) and F : tumor area microdissected for the molecular analysis (400x); D and G : Genomic profile plots of the PBT and corresponding CRC, respectively; H . Next generation sequencing analysis of CRCs and corresponding PBTs showing the retention of specific somatic variants on the TP53 , KDR , PIK3CA , CDKN2 and JAK3 genes in the CRCs.
    Pbt, supplied by Valiant, used in various techniques. Bioz Stars score: 93/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Valiant
    Average 93 stars, based on 16 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    93/100 stars
      Buy from Supplier

    82
    Thermo Fisher plasmid pbt
    Primary breast tumor <t>(PBT)</t> and corresponding <t>CRC</t> of case 6, representative of the TNBC subtype. A : Phase contrast image of CRC co-culture, showing the feeder cells (short arrows) and an epithelial cell colony (cobblestone cell morphology) (40x); B : Flow cytometry histogram showing CRC cells stained for PE/CD326 (EpCAM) (red peaks); unlabeled control (black peaks). Number of gated cells > 10,000; C : Ploidy analysis showing a DNA index of 3.01(G1 aneuploidy yellow peak) in relation to the diploid control (Peripheral Blood Lymphocyte (PBL)—G1 diploid red peak); E : FFPE tissue section (40x) and F : tumor area microdissected for the molecular analysis (400x); D and G : Genomic profile plots of the PBT and corresponding CRC, respectively; H . Next generation sequencing analysis of CRCs and corresponding PBTs showing the retention of specific somatic variants on the TP53 , KDR , PIK3CA , CDKN2 and JAK3 genes in the CRCs.
    Plasmid Pbt, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 82/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasmid pbt/product/Thermo Fisher
    Average 82 stars, based on 8 article reviews
    Price from $9.99 to $1999.99
    plasmid pbt - by Bioz Stars, 2020-03
    82/100 stars
      Buy from Supplier

    90
    Keysight Technologies pbt
    Small protein B (SmpB) enhanced enhanced green fluorescent protein (eGFP) production under the control of bvgS promoter. (A) Schematic representation of the constructs. The promoter and initial nine-residue of N-terminal BvgS were fused to eGFP, and introduced between pBR322 origin and ampicillin resistance gene to generate pDH114 by restriction sites Eag I and <t>Bgl</t> II. The native promoter and smpB gene, the native smpB promoter, the native promoter and encoded gene of GST were inserted between tetracyclin resistant gene and p15A origin to produce pDH212, pDH213, pDH214 using Nco I and Xho I, respectively. (B) Time courses of relative fluorescence in Escherichia coli Δ tmRNA-smpB co-transformed pDH114 with pDH212, pDH213, and pDH214, separately. The fluorescence of cells was measured and normalized to corresponding OD 600 . Error bars represented the SD of three independent cultures. (C) Column graph comparing the relative fluorescence at 24 h. (D) Time courses of relative fluorescence in E. coli two-hybrid reporter strains co-transformed pDH114 with <t>pBT</t> and pBT-SmpB, separately. The strains were induced by 1 mM IPTG at 37°C compared with the uninduced ones. (E) Column graph comparing the relative fluorescence in pBT and pBT-SmpB after 24 h IPTG treatments.
    Pbt, supplied by Keysight Technologies, used in various techniques. Bioz Stars score: 90/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Keysight Technologies
    Average 90 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    90/100 stars
      Buy from Supplier

    pbt  (Stanbio)
    90
    Stanbio pbt
    Small protein B (SmpB) enhanced enhanced green fluorescent protein (eGFP) production under the control of bvgS promoter. (A) Schematic representation of the constructs. The promoter and initial nine-residue of N-terminal BvgS were fused to eGFP, and introduced between pBR322 origin and ampicillin resistance gene to generate pDH114 by restriction sites Eag I and <t>Bgl</t> II. The native promoter and smpB gene, the native smpB promoter, the native promoter and encoded gene of GST were inserted between tetracyclin resistant gene and p15A origin to produce pDH212, pDH213, pDH214 using Nco I and Xho I, respectively. (B) Time courses of relative fluorescence in Escherichia coli Δ tmRNA-smpB co-transformed pDH114 with pDH212, pDH213, and pDH214, separately. The fluorescence of cells was measured and normalized to corresponding OD 600 . Error bars represented the SD of three independent cultures. (C) Column graph comparing the relative fluorescence at 24 h. (D) Time courses of relative fluorescence in E. coli two-hybrid reporter strains co-transformed pDH114 with <t>pBT</t> and pBT-SmpB, separately. The strains were induced by 1 mM IPTG at 37°C compared with the uninduced ones. (E) Column graph comparing the relative fluorescence in pBT and pBT-SmpB after 24 h IPTG treatments.
    Pbt, supplied by Stanbio, used in various techniques. Bioz Stars score: 90/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pbt/product/Stanbio
    Average 90 stars, based on 4 article reviews
    Price from $9.99 to $1999.99
    pbt - by Bioz Stars, 2020-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    Assays for the interaction between HpoR and LtmA. ( A ) Bacterial two-hybrid assays (Stratagene) for the interaction between HpoR and LtmA. Left panel, plate minus streptomycin (str) and 5 mM 3-amino-1,2,4-triazole (3-AT). Right panel, plate plus str and 5 mM 3-AT. CK + , co-transformant containing pBT-LGF2 and pTRG-Gal11 P was used as a positive control. CK − , co-transformant containing pBT and pTRG was used as a negative control. ( B ) SPR assays for the specific interaction between HpoR and LtmA. HpoR was immobilized on the CM5 chip, and different concentrations of LtmA were passed over the chip.

    Journal: Nucleic Acids Research

    Article Title: Cyclic di-GMP integrates functionally divergent transcription factors into a regulation pathway for antioxidant defense

    doi: 10.1093/nar/gky611

    Figure Lengend Snippet: Assays for the interaction between HpoR and LtmA. ( A ) Bacterial two-hybrid assays (Stratagene) for the interaction between HpoR and LtmA. Left panel, plate minus streptomycin (str) and 5 mM 3-amino-1,2,4-triazole (3-AT). Right panel, plate plus str and 5 mM 3-AT. CK + , co-transformant containing pBT-LGF2 and pTRG-Gal11 P was used as a positive control. CK − , co-transformant containing pBT and pTRG was used as a negative control. ( B ) SPR assays for the specific interaction between HpoR and LtmA. HpoR was immobilized on the CM5 chip, and different concentrations of LtmA were passed over the chip.

    Article Snippet: Cotransformants containing pBT-LGF2 and pTRG-Gal11P (Stratagene) were used as the positive controls for an expected growth on the screening medium.

    Techniques: Positive Control, Negative Control, SPR Assay, Chromatin Immunoprecipitation

    Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic iPSC ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor PBT and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )

    Journal: Cancer Science

    Article Title: Toward the development of true “off‐the‐shelf” synthetic T‐cell immunotherapy. Toward the development of true “off‐the‐shelf” synthetic T‐cell immunotherapy

    doi: 10.1111/cas.13892

    Figure Lengend Snippet: Schema of induced pluripotent stem ( iPS )‐based allogeneic T‐cell immunotherapy. 1. General schema illustrating autologous T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD 3, and subsequently transduced with a viral vector harboring a chimeric antigen receptor or a T‐cell receptor. The expanded cells are washed and cryopreserved for quality control ( QC ) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral vector before patient selection. This leads to off‐the‐shelf allogeneic T‐cell immunotherapy. 3. Perspective schema of allogeneic iPSC ‐derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working cell bank is generated for multiple (10‐1000) doses. Following patient identification, a vial is shipped to an infusion center and the product is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for autologous infusion include failure to obtain a sufficient number of PBMC s from the patient at apheresis, unsuccessful expansion after T cell activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of healthy donor PBT and iPSC ‐T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC ‐derived T cell infusion would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this figure is modified from Clarke et al. 49 )

    Article Snippet: Compared to the development of healthy donor PBT approaches, iPSC‐derived T cells are still in the preclinical stage of development.

    Techniques: Selection, Transduction, Plasmid Preparation, Derivative Assay, Generated, Activation Assay, Modification

    Primary breast tumor (PBT) and corresponding CRC of case 6, representative of the TNBC subtype. A : Phase contrast image of CRC co-culture, showing the feeder cells (short arrows) and an epithelial cell colony (cobblestone cell morphology) (40x); B : Flow cytometry histogram showing CRC cells stained for PE/CD326 (EpCAM) (red peaks); unlabeled control (black peaks). Number of gated cells > 10,000; C : Ploidy analysis showing a DNA index of 3.01(G1 aneuploidy yellow peak) in relation to the diploid control (Peripheral Blood Lymphocyte (PBL)—G1 diploid red peak); E : FFPE tissue section (40x) and F : tumor area microdissected for the molecular analysis (400x); D and G : Genomic profile plots of the PBT and corresponding CRC, respectively; H . Next generation sequencing analysis of CRCs and corresponding PBTs showing the retention of specific somatic variants on the TP53 , KDR , PIK3CA , CDKN2 and JAK3 genes in the CRCs.

    Journal: PLoS ONE

    Article Title: Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors

    doi: 10.1371/journal.pone.0186190

    Figure Lengend Snippet: Primary breast tumor (PBT) and corresponding CRC of case 6, representative of the TNBC subtype. A : Phase contrast image of CRC co-culture, showing the feeder cells (short arrows) and an epithelial cell colony (cobblestone cell morphology) (40x); B : Flow cytometry histogram showing CRC cells stained for PE/CD326 (EpCAM) (red peaks); unlabeled control (black peaks). Number of gated cells > 10,000; C : Ploidy analysis showing a DNA index of 3.01(G1 aneuploidy yellow peak) in relation to the diploid control (Peripheral Blood Lymphocyte (PBL)—G1 diploid red peak); E : FFPE tissue section (40x) and F : tumor area microdissected for the molecular analysis (400x); D and G : Genomic profile plots of the PBT and corresponding CRC, respectively; H . Next generation sequencing analysis of CRCs and corresponding PBTs showing the retention of specific somatic variants on the TP53 , KDR , PIK3CA , CDKN2 and JAK3 genes in the CRCs.

    Article Snippet: The affected cytobands and the type of CNAs observed (gain/amplifications and/or loss/deletions) between each paired CRC/PBT presented 72–100% of overlapping levels, as reported by the common interval analysis (Agilent Cytogenomics v.2.9.2.4 software).

    Techniques: Co-Culture Assay, Flow Cytometry, Cytometry, Staining, Formalin-fixed Paraffin-Embedded, Next-Generation Sequencing

    Small protein B (SmpB) enhanced enhanced green fluorescent protein (eGFP) production under the control of bvgS promoter. (A) Schematic representation of the constructs. The promoter and initial nine-residue of N-terminal BvgS were fused to eGFP, and introduced between pBR322 origin and ampicillin resistance gene to generate pDH114 by restriction sites Eag I and Bgl II. The native promoter and smpB gene, the native smpB promoter, the native promoter and encoded gene of GST were inserted between tetracyclin resistant gene and p15A origin to produce pDH212, pDH213, pDH214 using Nco I and Xho I, respectively. (B) Time courses of relative fluorescence in Escherichia coli Δ tmRNA-smpB co-transformed pDH114 with pDH212, pDH213, and pDH214, separately. The fluorescence of cells was measured and normalized to corresponding OD 600 . Error bars represented the SD of three independent cultures. (C) Column graph comparing the relative fluorescence at 24 h. (D) Time courses of relative fluorescence in E. coli two-hybrid reporter strains co-transformed pDH114 with pBT and pBT-SmpB, separately. The strains were induced by 1 mM IPTG at 37°C compared with the uninduced ones. (E) Column graph comparing the relative fluorescence in pBT and pBT-SmpB after 24 h IPTG treatments.

    Journal: Frontiers in Microbiology

    Article Title: Small protein B upregulates sensor kinase bvgS expression in Aeromonas veronii

    doi: 10.3389/fmicb.2015.00579

    Figure Lengend Snippet: Small protein B (SmpB) enhanced enhanced green fluorescent protein (eGFP) production under the control of bvgS promoter. (A) Schematic representation of the constructs. The promoter and initial nine-residue of N-terminal BvgS were fused to eGFP, and introduced between pBR322 origin and ampicillin resistance gene to generate pDH114 by restriction sites Eag I and Bgl II. The native promoter and smpB gene, the native smpB promoter, the native promoter and encoded gene of GST were inserted between tetracyclin resistant gene and p15A origin to produce pDH212, pDH213, pDH214 using Nco I and Xho I, respectively. (B) Time courses of relative fluorescence in Escherichia coli Δ tmRNA-smpB co-transformed pDH114 with pDH212, pDH213, and pDH214, separately. The fluorescence of cells was measured and normalized to corresponding OD 600 . Error bars represented the SD of three independent cultures. (C) Column graph comparing the relative fluorescence at 24 h. (D) Time courses of relative fluorescence in E. coli two-hybrid reporter strains co-transformed pDH114 with pBT and pBT-SmpB, separately. The strains were induced by 1 mM IPTG at 37°C compared with the uninduced ones. (E) Column graph comparing the relative fluorescence in pBT and pBT-SmpB after 24 h IPTG treatments.

    Article Snippet: The fragment was cut with Eco R I/Bgl II and inserted into pBT (Keysight Technologies, Santa Clara, CA, USA).

    Techniques: Construct, Fluorescence, Transformation Assay